Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

203 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-16

Study Completion Date

2021-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to determine in a case-control study if an association exist between bone marrow adiposity and fragility fractures in post-menopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bone Fragility Evaluation in Obese Patients

NCT04174495

Obesity Bariatric Surgery Candidate

COMPLETED

Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density

NCT01250314

Osteoporosis

COMPLETED NA

MRI Study of the Distal Radius Bone Marrow Fat Fraction in Osteoporotic and Healthy Women

NCT03742362

Osteoporosis, Postmenopausal

COMPLETED NA

Evaluation of Osteoporosis Support After a Severe Osteoporotic Fracture in Women Over 50 Years in University Hospital

NCT02924545

Osteoporosis

COMPLETED

Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women

NCT03798444

Osteoporosis Fracture

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fractures, Bone Bone Marrow Disease Fat Disorder Adiposity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (cases)

occurence of incident major osteoporotic fracture less than 12 weeks

Dixon Magnetic Resonance Imaging

Intervention Type DEVICE

MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.

Group 2 (controls)

no history of fragility fracture

dual-energy X-ray absorptiometry (DXA)

Intervention Type DEVICE

Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dixon Magnetic Resonance Imaging

MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.

Intervention Type DEVICE

dual-energy X-ray absorptiometry (DXA)

Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* post-menopausal women : 50-90 years old
* Group 1 (cases) : occurence of incident major osteoporotic fracture less than 12 months
* Group 2 (controls) : no history of fragility fracture

Exclusion Criteria

* Implants that are contraindicated for the magnetic resonance (MR) examination.
* Implants that might create a health risk or other problem during an MR exam include: 1) cardiac pacemaker or implantable defibrillator, 2) catheter that has metal components that may pose a risk of a burn injury, 3) a ferromagnetic metal clip placed to prevent bleeding from an intracranial aneurysm, 4) an implanted medication pump (such as that used to deliver insulin or a pain-relieving drug), and 5) a cochlear implant.
* body mass index \[BMI\] \>38 kg/m2, weight \>140 kg
* Disease or current use of medications known to affect bone density, including oral glucocorticoids, treatments for osteoporosis (bisphosphonates, raloxifene, calcitonin, or PTH), hormone therapy.
* Chronic kidney disease with DFG \<30 ml/mn

Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes